Trial Profile
A phase II trial of docetaxel in the treatment of elderly patients (aged 70 or over) with non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ELTAX
- 01 Aug 2012 Actual end date (Jan 2009) added as reported by ISRCTN: Current Controlled Trials record.
- 01 Aug 2012 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials record.
- 01 Jan 2009 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.